September 6, 2018 Bio/Pharma/CRO

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC

Basel, 06 September 2018 Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC Roche (SIX: RO, ROG; OTCQX: RHHBY). On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ® (atezolizumab)... Read more

September 6, 2018 Bio/Pharma/CRO

Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)

Basel, 06 September 2018 Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the TECENTRIQ lung programme, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer New... Read more

September 3, 2018 Bio/Pharma/CRO PR/Corporate

Reminder: Invitation to Roche's Virtual Late Stage Pipeline Event 2018

Basel, 03 September 2018 Reminder: Invitation to Roche’s Virtual Late Stage Pipeline Event 2018 We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio.   The Roche Virtual Late Stage Pipeline Event... Read more

August 30, 2018 Bio/Pharma/CRO

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more

August 30, 2018 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more

August 28, 2018 Bio/Pharma/CRO PR/Corporate

Changes to the Roche Corporate Executive Committee

Basel, 28 August 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer,... Read more

August 28, 2018 Uncategorized

Changes to the Roche Corporate Executive Committee

Basel, 28 August 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer,... Read more

August 22, 2018 Chromatography Licensing, IP, and Legal PR/Corporate

Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer

Basel, 22 August 2018 Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 25 September 2018, highlighting the results... Read more

August 20, 2018 Bio/Pharma/CRO

China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer

Basel, 20 August 2018 China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China, just eight and nine months after EMA and FDA approvals, respectively Supporting data showed Alecensa significantly reduced the risk of disease progression or death by... Read more

August 13, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies

Basel, 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies As many as 15 million Americans have food allergies – including approximately 6 million children – and the incidence is increasing Roche (SIX: RO, ROG;... Read more